Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3000 participants.

Also called NCT04700826

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04700826
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04700826. Randomized; no masking; primary purpose prevention. Start 2021-06-01 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
Acronym
DaRe2THINK
Intervention (Drug)
Direct Oral Anticoagulants
Lead sponsor
University of Birmingham (class: other)
Collaborator
Clinical Practice Research Datalink (class: other government)
Collaborator
University Hospital Birmingham NHS Foundation Trust (class: other)
Collaborator
University of Oxford (class: other)
Collaborator
London School of Economics and Political Science (class: other)
Collaborator
Aston University (class: other)

Record details

Record id
cardio:ct-nct04700826
Content hash
36a7b0ecc31c6c6d0aea72835710fa59113e8035d9e7216e1bdd81ba60e048db